Publication at Third Faculty of Medicine |
2022
Abstract
Immunotherapy in monotherapy or in combination with chemotherapy dominates the first-line treatment of non-small cell lung cancer. There are several reimbursed treatment regimens available.
For treatment selection, patient performance status and PD-L1 expression are important. In patients, in which immunotherapy is contraindicated due to comorbidities or poor performance status, platinum-based chemotherapy in combination preferably with pemetrexed or bevacizumab is indicated.
The following text summarizes recent findings from clinical trials and recommended treatment.